Posted by Michael Wonder on 18 Nov 2019
Ontario and Quebec provide reimbursement for HIV therapies Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)
18 November 2019 - For more than 30 years, Merck has been committed to scientific research and discovery in HIV that addresses unmet medical needs and helps people living with HIV have a long and healthy life.
Merck Canada announced today that reimbursement will be provided to Pifeltro and Delstrigo a once-daily NNRTI regimen for the treatment of HIV-1 infection, effective October 31st for the Ontario Drug Benefit Program and November 14th for la Régie de l'assurance maladie du Québec, RAMQ. Ontarians and Quebecers aged 18 years or older who are living with an HIV-1 infection will be eligible for reimbursement under the public program.
Merck’s Pifeltro and Delstrigo were approved for the treatment of HIV-1 by Health Canada in 2018. Both treatments provide additional options to adults infected with HIV-1 to help manage their disease.
